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CD300A AND CD300C ON PLASMACYTOID DENDRITIC CELLS ARE
DOWN-REGULATED BY TLR7 AND TLR9 LIGAND INDUCED TYPE I IN-
TERFERON
Hart, D.N.J.1, Clark, G.1, Ju, X.1, Zenke, M.2. 1Mater Medical Re-
search Institute, Brisbane, Queensland, Australia; 2 Institute for Biomed-
ical Engineering, Aachen, Germany.
Plasmacytoid dendritic cells (pDC) constitute a distinct popula-
tion of DC in the peripheral and secondary lymphoid organs. After
activation with the ligands for Toll-like receptors (TLRs), particu-
larly TLR7 and TLR9, pDC secrete large amounts of type I inter-
ferons and differentiate into mature DC, expressing co-stimulatory
molecules and other cytokines. New immunoregulatory molecules
on humanpDCwere sought and their regulation byTLR ligands as-
sessed by pDC gene expression profiling. We established that both
the CD300a and CD300c cell surface molecules are expressed by
pDC. Because CD300 molecules play important roles in regulating
immune responses, we investigated their contribution to pDC func-
tion in more detail. First, their down-regulation by CpG-ODNwas
confirmedby real timePCRandRT-PCR forCD300a andCD300c.
Using the monoclonal antibody CMRF-35, to detect both CD300a
and CD300c, we demonstrated that both TLR7 and TLR9 ligands
down-regulated cell surface CD300a and CD300c. We showed
that exogenous IFN-a down-regulated CD300a/c expression in
pDC suggesting that the TLR ligands induced down-regulation of
CD300a/c might be an indirect effect. In subsequent experiments,
we added neutralizing antibody to IFN-a and found that it abolished
the CpG-ODN induced CD300a/c down-regulation.
The effect of CD300a and CD300c activation on the function of
pDC was investigated by cross-linking CMRF-35 on pDC. This
had no effect on CD80, CD83 and CD86 expression, but decreased
MHC-II expression. Significant reductions in pDCTNF-a and IL-
6 production occurred after CMRF-35 cross-linking, however, in
marked contrast, CpG-ODN induced IFN was increased in these
experiments. Thus the immune regulators CD300a and CD300c
regulate the cytokine production in pDC, whilst the pDC released
cytokines regulated the CD300a/c expression. This suggests that
CD300molecules may play a pivotal role in fine tuning pDC driven
immune responses and may contribute to the pDC biology of allo-
geneic bone marrow transplantation.320
RECENT TRENDS IN UNRELATED DONOR STEM CELL TRANSPLANTA-
TION: A REPORT FROM THE ABMTRR
Nivison-Smith, I.1, Bradstock, K.F.2, Dodds, A.J.3, Ma, D.D.F.3,
Szer, J.4. 1ABMTRR, Darlinghurst, NSW, Australia; 2Westmead Hospi-
tal, Westmead, NSW, Australia; 3St Vincent’s Hospital, Darlinghurst,
NSW,Australia; 4RoyalMelbourneHospital, Parkville, Victoria, Australia.
Aim: To investigate and highlight recent trends among patients
undergoing allogeneic haematopoietic stem cell transplant
(HSCT) with unrelated donors (URD) in Australia and New Zea-
land.Methods:Patients were selected from the database of the Aus-
tralasian Bone Marrow Transplant Recipient Registry (ABMTRR).
Patients selected for this study had undergone HSCT with URD
between the years of 2001 and 2006. Results: A total of 891 alloge-
neic HSCT with URD were performed in the years 2001 to 2006.
The annual numbers have increased steadily, from 101 in 2001 to
172 in 2005 and 146 in 2006. A total of 257 HSCT (29%) involved
patients aged up to 15 years, and 634 (71%) involved patients aged
16 or over. Among paediatric transplants, 128 (50%) utilised cord
blood (including double cord), 96 (37%) utilised bone marrow
and 33 (13%), peripheral blood. Themajor indication for transplant
in paediatric HSCT was ALL (79, 31% of paediatric HSCT).
Among adult transplants, the stem cell source was peripheral blood
in 407 (64%), marrow in 188 (30%) and cord blood in 39 (6%). The
major indication for adult transplant was AML (228, 36% of adult
HSCT). The number of adult HSCT for patients aged 50 years
or over increased from 20 in 2001 to 39 in 2006. The number
of adult HSCT involving reduced intensity conditioning also
increased, from 11 in 2001 to 48 in 2005 and 30 in 2006.
Conclusions: The annual numbers of URD HSCT in Australasia
have increased steadily in recent years. Recent trends in practice in-clude increases in numbers of older patients and HSCT using re-
duced intensity conditioning. The ABMTRR is a valuable
national resource which provides accurate and timely information
on HSCT activity and outcome in these two countries.321
EFFICACY AND TOXICITY OF A CONDITIONING REGIMEN WITH 8-GY
TOTAL BODY IRRADIATION, FLUDARABINE AND CYCLOPHOSPHAMIDE
FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PEDIATRIC HEMATOLOGIC MALIGNANCIES
Yanagisawa, R.1, Nakazawa, Y.1, Sakashita, K.1, Tanaka, M.1,
Kamijo, T.2, Shiohara, M.1, Koike, K.1. 1Shinshu University School of
Medicine, Matsumoto, Japan; 2Chiba Cancer Center Research Institute,
Chiba, Japan.
We examined the efficacy and toxicity of a conditioning regimen
with fractionated 8-Gy total body irradiation, fludarabine, and cyclo-
phosphamide in allogeneic hematopoietic stem cell transplantation
(HSCT) for pediatric hematologic malignancies. Among a total of
22childrenwho received relatedorunrelatedHSCT,ninewere trans-
planted with refractory disease and/or fromHLA2 ormore-loci mis-
matched family donors. The Seattle grading system revealed that 18
patients had no regimen-related toxicity, whereas the remaining
patients had grade I gastrointestinal toxicity alone. According to the
National Cancer Institute Common Toxicity Criteria, Grade II or
higher toxicity in the liver, mucosa, and gastrointestinal tract among
eight organs was documented in approximately 10–35% of patients,
and was attributed to engraftment syndrome and/or acute graft-ver-
sus-host disease. None of the patients developed graft failure. The
estimated overall survival and leukemia-free survival (LFS) at 2 years
were 56.3% and 46.7%, respectively, in 10 patients with acute
lymphoblastic leukemia; 91.7% and 81.5%, respectively, in 12 pa-
tients with myeloid leukemia. The incidence of treatment-related
mortality was 5.3% at 2 years. It is possible that our preparative reg-
imen confers successful engraftment combined with minimized regi-
men-related toxicity, and a favorable LFS rate for children with
hematologic malignancies, especially for those with myeloid leukemia.322
ROLE OF RITUXIMAB FOR PROPHYLACTIC OR PREEMPTIVE THERAPY
OF EBV-DNA-emia AND THERAPY OF EBV-PTLD IN HSCT RECIPIENTS:
A SYSTEMATIC REVIEW
Styczynski, J.1, Einsele, H.2, de la Camara, R.3, Engelhard, D.4,
Reusser, P.5, Ward, K.N.6, Ljungman, P.7. 1Collegium Medicum
UMK, Bydgoszcz, Poland; 2University Hospital, Wuerzburg, Germany;
3Hospital de la Princesa, Madrid, Spain; 4Hadassah University Hospital,
Jerusalem, Israel; 5Basel University School of Medicine, Porrentruy,
Switzerland; 6University College London, London, United Kingdom;
7Karolinska University Hospital, Stockholm, Sweden.
Objective: To evaluate the role of rituximab for prevention and
treatment of posttransplant lymphoproliferative disorder (EBV-
PTLD) in HSCT recipients. DATA SOURCES: A PubMed search
(1966-September 2007) was conducted using the key words: EBV,
posttransplant lymphoproliferative disorder, stem cell transplanta-
tion, rituximab. References of relevant articles and abstracts from
recent hematology and stem cell transplantation scientific meetings
(2003–2007) were also reviewed. STUDY SELECTION AND
DATA EXTRACTION: Prospective and retrospective studies
identified from the data sources were evaluated, and all data deemed
relevant were included in this analysis. DEFINITIONS: Prophy-
laxis of EBV-DNA-emia (EBV reactivation) – rituximab given to se-
ropositive, EBV-DNA-negative patient (or when donor was
seropositive) to prevent EBV reactivation. Preemptive therapy – rit-
uximab given to an asymptomatic patient with EBV detected by
a screening assay. Treatment of PTLD – rituximab applied to a pa-
tient with an overt EBV-PTLD. Results: High risk HSCT for
PTLDdevelopment were allogeneicHSCTwith following risk fac-
tors: unrelated/mismatch HSCT; T-cell depletion or ATG/OKT3
use; EBV serology mismatch; primary EBV infection; splenectomy.
The risk increased with the number of risk factors. In addition to
quantification of EBV DNA load, analysis of the level of EBV-spe-
cific T cell reconstitution during EBV reactivation might be an
Poster Session II 119important second parameter to define patients at risk for EBV-
PTLDwhomight be candidates for preemptive interventions.Total
number of 49 papers and 19 conference abstracts were available.
Most reports included only a small number of patients. Overall re-
sponse rateswere: 61% (14/23 pts) for prophylactic use of rituximab;
88% (214/243 pts) for preemptive therapy with rituximab, and 72%
(56/77 pts) for rituximab used for therapy of EBV-PTLD disease.
Rituximab was safe and well tolerated.Conclusions: Since a signif-
icant proportion of patients died from PTLD in spite of rituximab
treatment, and since availability of EBV-CTLs is limited, it is rea-
sonable to recommend preemptive treatment with rituximab for in-
creasing EBV-DNA-emia. Emerging problem might be related to
down-regulation of CD20 expression on PTLD cells following re-
peated therapy, causing refractoriness to rituximab treatment due to
lack of CD20 expression. Further studies are needed to confirm the
efficacy of these treatment strategies.323
CHRONIC GRAFT VERSUS HOST DISEASE AND PRETRANSPLANT DIS-
EASE STATUS PREDICT OUTCOMES IN PATIENTS WITH HEMATOLOGIC
MALIGNANCIES UNDERGOING REDUCED INTENSITY ALLOGENEIC
STEM CELL TRANSPLANTATION
Shah, M., Agha, M., Mapara, M., Lenhart, K., Raptis, A. University of
Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine,
Pittsburgh, PA.
Reduced intensity stem cell transplantation (SCT) is an effective
treatmentmodality for patients with hematologicmalignancies who
are not candidates for conventional myeloablative SCT. We con-
ducted a retrospective review of all patients with hematologicmalig-
nancies receiving a reduced intensity allogeneic SCT from July
2002 to July 2007. Data pertaining to patient demographics, en-
graftment, disease status pre/post transplant, graft versus host dis-
ease (GVHD), and HLA matching was analyzed to identify
factors significantly affecting the clinical outcome.
73 patients, with a median age of 55 (range of 19–70) and with the
diagnoses of ALL (n5 8), AML (n5 30), CLL (n5 3), CML (n5
1), Hodgkins (n 5 7), non-Hodgkins (n 5 7), MDS (n 5 11), and
MM (n5 6) underwent a reduced intensity SCT using a fludarabine
based conditioning regimen. Median and mean follow-up times
were 5.6 and 9.9 months respectively. 39 (53%) received unrelated
donor grafts and 34 (47%) received sibling donor grafts. 56 patients
(77%) received fully matched grafts whereas 17 patients (23%) had
an antigen or allele mismatch. Neither of those variables affected
clinical outcome. Median time to neutrophil recovery was 15 days
(range of 9–41) and median time to platelet recovery was 18 days
(range of 9–42). Graft failure was observed in 6 of the 73 patients.
Median overall survival and disease free survival for all patients
was 7.7 and 6.6 months. Median overall survival for patients with
persistent disease or in remission at the time of the SCT was 5.6
and 21.8 months (p 5 0.01) while that for disease free survival was
5.7 and 8.4 months (p 5 0.06). Median overall survival with and
without chronicGVHDwas 25.6 and 9.4months (p\0.0001) while
median disease free survival was 18.2 and 6.0 months (p\ 0.0001).
Patients with limited chronic GVHD have not yet reached median
overall survival while median disease free survival was 18.4 months.
Those with extensive chronic GVHD had medians of 9.2 months
for both overall and disease free survival (p 5 0.004 and p 5 0.02).
Reduced intensity SCT is an effective treatment modality in pa-
tients with hematologic malignancies, though it is most effective in
patients who are in remission at the time of transplant and should be
offered in this setting. Patients with limited chronic GVHD had
a better outcome suggesting the presence of potent anti-tumor ac-
tivity of the donor immune competent cells without the detrimental
effects in clinical outcome caused by extensive chronic GVHD.324
THE FEASIBILITY OF USING CCR5D32/D32 HEMATOPOIETIC STEM CELL
TRANSPLANTS FOR IMMUNE RECONSTITUTION IN HIV-INFECTED CHIL-
DREN
Chen, T.K.1, Moore, T.B.2, Territo, M.3, Chow, R.4, Tonai, R.4,
Petz, L.4, Rossi, J.5, Mitsuyasu, R.3, Rosenthal, J.6, Forman, S.6,Zaia, J.A.5, Bryson, Y.J.1. 1David Geffen School of Medicine at
UCLA, Los Angeles, CA; 2David Geffen School of Medicine at UCLA,
Los Angeles, CA; 3David Geffen School of Medicine at UCLA, Los An-
geles, CA; 4StemCyte, Inc., Covina, CA; 5Beckman Research Institute
of City of Hope, Duarte, CA; 6Beckman Research Institute of City of
Hope, Duarte, CA.
Despite treatment with highly-active antiretroviral therapy
(HAART), someHIV infected patients fail to reconstitute their im-
mune functions and are intolerant to side effects of long term
HAART, indicating the need to develop novel immune-based ther-
apies. Hematopoietic stem cells (HSC) have been used to reconsti-
tute the immune system in patients with primary
immunodeficiencies, genetic diseases, and childhood cancers.
Transplantation for HIV infection has been attempted, but re-in-
fection of the grafted cells is a concern. Studies demonstrate that ho-
mozygosity for a 32 bp deletion in the HIV-1 CCR5 co-receptor
gene (CCR5D32) is associated with protection against R5 HIV in-
fection, while CCR5D32 heterozygosity is associated with slower
disease progression. Thus, T-cells developing after a transplant
withHSC homozygous for the CCR5D32mutation should be resis-
tant to R5 HIV infection. The CCR5D32 allele is found in Cauca-
sian populations with 1% being homozygous and 15–20%
heterozygous. We have shown that the HIV coreceptor tropism
may revert from X4 to R5 under the pressure of HAART. In addi-
tion, we and others have found that the replication competent virus
recovered fromCD4T-cells reservoirs in children are R5.We eval-
uated the feasibility of HSC transplantation using CCR5D32/D32
stem cells for the immune reconstitution of HIV-infected children
who are immunocompromised despite HAART. StemCyte, an in-
ternational cord blood bank, has been actively screening their
cord blood units (CBUs) for the CCR5D32 allele. To date, Stem-
Cyte has identified 30 homozygotes and 754 heterozygotes for the
CCR5D32 mutation among 10,488 CBUs screened. 44 patients
were randomly selected from our cohort of HIV-infected children
and adolescents. HLA typing was performed to identify patients
with potential HLA matched CBUs. Initial statistical consider-
ations demonstrated that 100–150 patients would need to be
screened in order to identify 2–4 potential HLA matched CBUs.
We found 7 (15.9%) of our patients with a 4/6 HLA match to the
identified homozygous CBUs, and 20 (45.4%) of our patients that
are a 3/6 match to the identified homozygous CBUs. 2 of 7 patients
with an identified 4/6 HLA match continue to have detectable
plasma viremia despite HAART. 2 of 7 patients have cords with suf-
ficient cell count for transplant. Thus, we identified and character-
ized 7 potential HIV-positive patients who could benefit from
a transplant ofHLA-matched, CCR5D32/D32 umbilical cord blood
stem cells.HLAmatched (4 out of 6) patients and homozygous CCR5D32 cord blood
units
Patient Cord Blood UnitAge GenderWeight
(kg) GenderVolume
(mL)TNC/kg
(107)
CD34/kg
(105)
Mismatched
loci17 years M 70.1M 95.0 0.61 0.18 BM 64.68 0.81 0.26 B, DRB1F 64.20 1.07 0.18 B, DRB1M 67.00 1.50 0.21 A, DRB111 years M 41.3F 64.20 1.82 0.30 A, B5 years M 23.2M 64.68 2.46 0.78 A, B25 years M 60.9F 152.20 5.77 2.17 B, DRB124 years M 70.4M 64.29 0.97 0.14 A, DRB111 years F 42.6F 63.80 1.55 0.31 A, B22 months M 12.7F 64.20 5.92 0.97 A, B
